Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2025

Congress Details

November 7-10, 2025

New Orleans, Louisiana

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Congress Materials

Razvi_AHA-2025_H-B-Cardiac-MRI-Poster-FINAL-Nov-7

Presentation Type

Poster

Location

New Orleans, Louisiana

Title

Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial

Manafi_AHA25_H-B-RVFWS-poster_05Nov25_FINAL

Presentation Type

Poster

Location

New Orleans, Louisiana

Title

Right Ventricular Free Wall Strain and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy and Effect of Vutrisiran: The HELIOS-B Study

Jering_AHA-LAS-HELIOS-B-20251104_FINAL_updated

Presentation Type

Poster

Location

New Orleans, Louisiana

Title

Left Atrial Strain and Clinical Outcomes in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the HELIOS-B Trial on Vutrisiran Efficacy

Sheikh_AHA-2025-H-B-Renal-Pos_D6.0_05Nov_FINAL

Presentation Type

Poster

Location

New Orleans, Louisiana

Title

Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B